XBIO.BK X Bioscience Public Company Limited
- Market cap
- THB 489M
- P/E
- -
- P/B
- 1.66x
- ROE
- -247.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is XBIO.BK undervalued?
Graham numberThe Graham number of X Bioscience Public Company Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
X Bioscience Public Company Limited fundamental analysis
No fundamental analysis for X Bioscience Public Company Limited yet.
X Bioscience Public Company Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About X Bioscience Public Company Limited
X Bioscience Public Company Limited, together with its subsidiaries, sells food and beverages in Thailand. It engages in the food and beverage investment and restaurant businesses. The company also manufactures and sells biological products, as well as generates and transmits electric power. Its brands include Kagonoya, Le Boeuf, and Bake Cheese Tart. The company was formerly known as Wow Factor Public Company Limited and changed its name to X Bioscience Public Company Limit…
Full company profileX Bioscience Public Company Limited financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
X Bioscience Public Company Limited annual financial statements (THB; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 183M | 230M | 298M | 425M | 416M | 412M | 344M | 312M | 319M | 130M | 320M |
| Gross Profit | 39.3M | 70.4M | 87.2M | 145M | 130M | 193M | 172M | 152M | 139M | 52.9M | 121M |
| Operating Income | -133M | -16.5M | 15.4M | -76.3M | -127M | -265M | -98.6M | -120M | -251M | -454M | -1.11B |
| EBITDA | -116M | -120M | 58.4M | 42.6M | -126M | 29.0M | -134M | -62.1M | -176M | -414M | -711M |
| Net Income | -135M | -132M | 5.23M | -21.9M | -237M | -276M | -331M | -148M | -260M | -469M | -731M |
| EPS | -24 | -20 | 0.41 | -0.47 | -0.34 | -0.34 | -0.41 | -0.17 | -0.19 | -0.62 | -0.06 |
| Balance Sheet | |||||||||||
| Total Assets | 387M | 813M | 776M | 1.26B | 1.28B | 1.32B | 700M | 739M | 1.41B | 609M | 641M |
| Total Liabilities | 74.4M | 261M | 219M | 292M | 332M | 647M | 598M | 557M | 587M | 386M | 283M |
| Shareholders' Equity | 313M | 552M | 557M | 788M | 948M | 673M | 103M | 183M | 514M | 217M | 295M |
| Cash & Short-term Investments | 146M | 256M | 99.1M | 53.7M | 43.4M | 28.0M | 16.2M | 26.7M | 9.19M | 1.57M | 5.30M |
| Total Debt | 32.0M | 137M | 94.3M | 111M | 201M | 469M | 473M | 415M | 355M | 240M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -31.8M | -8.60M | 20.2M | -32.0M | -30.1M | -139M | -152M | -76.3M | -37.4M | -91.4M | -197M |
| Capital Expenditure | 11.5M | 6.30M | 32.4M | 66.1M | 37.5M | 73.4M | 139M | 57.3M | 36.3M | 3.59M | 341M |
| Free Cash Flow | -43.3M | -14.9M | -12.2M | -98.1M | -67.6M | -213M | -291M | -134M | -73.8M | -95.0M | -537M |
| Ratios | |||||||||||
| ROE | -43.0% | -23.8% | 0.9% | -2.8% | -25.0% | -41.1% | -322.6% | -80.7% | -50.7% | -216.5% | -247.7% |
| ROA | -34.8% | -16.2% | 0.7% | -1.7% | -18.5% | -20.9% | -47.2% | -20.0% | -18.4% | -77.0% | -114.1% |
| Net Profit Margin | -73.5% | -57.2% | 1.8% | -5.2% | -57.1% | -67.0% | -96.0% | -47.3% | -81.5% | -361.9% | -228.6% |
| Debt to Equity | 0.10x | 0.25x | 0.17x | 0.14x | 0.21x | 0.70x | 4.61x | 2.27x | 0.69x | 1.11x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
X Bioscience Public Company Limited dividends
X Bioscience Public Company Limited has not paid dividends in the last 9 fiscal years.
Last stock split: 1:7 on Oct 3, 2025.
Who owns X Bioscience Public Company Limited
- Insiders 91.45%
- Institutions 0.00%
- Public & others 8.55%
- Shares outstanding 12.2B
- Free float 2.25B
X Bioscience Public Company Limited company profile
- Company name
- X Bioscience Public Company Limited
- Ticker
- XBIO.BK
- Exchange
- Thailand Exchange
- Sector
- Consumer Cyclical
- Industry
- Restaurants
- Fiscal year end
- December
- Address
- No. 304, Vanit Place Building A, Bangkok, Thailand, 10400
- Phone
- 66 2 278 5456
- Website
- xbio.co.th
About X Bioscience Public Company Limited
X Bioscience Public Company Limited, together with its subsidiaries, sells food and beverages in Thailand. It engages in the food and beverage investment and restaurant businesses. The company also manufactures and sells biological products, as well as generates and transmits electric power. Its brands include Kagonoya, Le Boeuf, and Bake Cheese Tart. The company was formerly known as Wow Factor Public Company Limited and changed its name to X Bioscience Public Company Limited in January 2025. X Bioscience Public Company Limited was founded in 1984 and is headquartered in Bangkok, Thailand.
X Bioscience Public Company Limited management
5- Mr. Amnart LertpresertwongCEO & Director · born 1973
- Mr. Ramjai SripromminCFO & Company Secretary · born 1977
- Mr. Michael FernandezDirector of Investments
- Mr. Pongsak NawalakDirector of Technology
- Ms. Nitchanun YammeesriCompany Secretary · born 1989